PT

Palvella Therapeutics, Inc.

PVLA·NASDAQ

$115.42

+10%
HealthcareBiotechnology

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

At a Glance

Live Snapshot
Market Cap$1.37B
EPS-3.7100
P/E Ratio-31.11
Earnings Date08/13/2026

pvla

Short Term Debt

Last Annual Value

202.00K

3-Year CAGR

%

5-Year CAGR

-28%

10-Year CAGR

-15%

PT

Palvella Therapeutics, Inc. Competitors Analysis of Short Term Debt

PVLA · NASDAQ
CompanyShort Term Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
202.00K
N/A-28.1%N/A 
472.00K
N/AN/AN/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
0.00
N/AN/AN/A
1.28M
N/AN/AN/A
SVRA logo
Savara Inc.
NASDAQ:SVRA
7.00K
N/A-75.7%N/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
0.00
N/AN/AN/A
588.00K
35.4%-29.9%N/A
547.00K
N/AN/AN/A
0.00
N/AN/AN/A
PT

Palvella Therapeutics, Inc. Fair Value Envelope

PVLA · NASDAQ

Our analysis suggests that PVLA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $115.42, this represents a potential HIDDEN relative to our calculated worth for Palvella Therapeutics, Inc..

Intrinsic Value
Current Price: $115.42